Neoleukin Therapeutics (NASDAQ:NLTX) Downgraded by ValuEngine

Share on StockTwits

Neoleukin Therapeutics (NASDAQ:NLTX) was downgraded by ValuEngine from a “hold” rating to a “sell” rating in a research note issued to investors on Tuesday, ValuEngine reports.

Shares of NLTX stock opened at $4.88 on Tuesday. The business has a 50 day simple moving average of $3.43. The company has a quick ratio of 26.35, a current ratio of 26.35 and a debt-to-equity ratio of 0.01. Neoleukin Therapeutics has a fifty-two week low of $2.00 and a fifty-two week high of $6.59.

Neoleukin Therapeutics (NASDAQ:NLTX) last issued its quarterly earnings results on Wednesday, November 13th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.04) by ($0.40).

Several large investors have recently added to or reduced their stakes in the company. Millennium Management LLC acquired a new position in shares of Neoleukin Therapeutics during the 3rd quarter valued at $1,166,000. California Public Employees Retirement System bought a new position in Neoleukin Therapeutics during the third quarter worth $162,000. Virtu Financial LLC bought a new position in Neoleukin Therapeutics during the third quarter worth $57,000. Finally, State Street Corp acquired a new stake in Neoleukin Therapeutics in the third quarter worth $35,000. Institutional investors own 66.90% of the company’s stock.

Neoleukin Therapeutics Company Profile

Neoleukin Therapeutics, Inc, a biopharmaceutical company, develops immunotherapies using protein design technology. The company's lead product candidate is NL-201, a computationally-designed de novo protein therapeutic for the treatment of IL-2/IL-15 cancer immunotherapy. It also engages in research activities for the treatment of autoimmunity and allergy.

Recommended Story: What is Elliott Wave theory?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Neoleukin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neoleukin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.